CSF3 and lymphoma: This analysis confirmed that patients receiving G-CSF were less likely to experience lymphoma progression (HR 0.40; 95% CI 0.18–0.87) than controls but were more likely to die prior to lymphoma progression (HR 3.08; 95% CI 1.05–8.99).